Dr Amandine Breton is currently a Cell Therapy Operations Manager at Orchard Therapeutics where she supports activities related to the transfer and oversight of manufacturing processes and controls to support Orchard’s product pipeline programs from pre-clinical through to commercialization. Prior to Orchard, her academic research experiences were centred on cell reprogramming and cell differentiation mechanisms (somatic cell nuclear transfer model and generation of induced pluripotent stem cell lines). She worked on regulators of globin genes in the context of sickle cell disease and beta-thalassaemia before moving into the cell therapy field. There she worked on technology transfer, process development and manufacture of cell therapy products (autologous T cells products, allogeneic hESC derived dendritic cell vaccine). She has a strong interest into translating academic research into robust GMP manufacturing processes and facilitating this critical step to enable innovative cell and gene therapy to be delivered to patients.